25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALPMY (Astellas) Stock Analysis
Buy, Hold or Sell?

Let's analyze Astellas together

I guess you are interested in Astellas Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Astellas’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Astellas’s Price Targets

I'm going to help you getting a better view of Astellas Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Astellas Pharma Inc

I send you an email if I find something interesting about Astellas Pharma Inc.

1. Quick Overview

1.1. Quick analysis of Astellas (30 sec.)










1.2. What can you expect buying and holding a share of Astellas? (30 sec.)

How much money do you get?

How much money do you get?
$0.49
When do you have the money?
1 year
How often do you get paid?
75.0%

What is your share worth?

Current worth
$5.66
Expected worth in 1 year
$5.27
How sure are you?
77.5%

+ What do you gain per year?

Total Gains per Share
$0.10
Return On Investment
0.8%

For what price can you sell your share?

Current Price per Share
$11.56
Expected price per share
$10.61 - $12.13
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Astellas (5 min.)




Live pricePrice per Share (EOD)
$11.56
Intrinsic Value Per Share
$8.54 - $19.12
Total Value Per Share
$14.20 - $24.78

2.2. Growth of Astellas (5 min.)




Is Astellas growing?

Current yearPrevious yearGrowGrow %
How rich?$10.2b$10.7b-$176.2m-1.7%

How much money is Astellas making?

Current yearPrevious yearGrowGrow %
Making money$86.2m$21.9m$64.3m74.6%
Net Profit Margin3.3%1.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Astellas (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Astellas?

Welcome investor! Astellas's management wants to use your money to grow the business. In return you get a share of Astellas.

First you should know what it really means to hold a share of Astellas. And how you can make/lose money.

Speculation

The Price per Share of Astellas is $11.56. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Astellas.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Astellas, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.66. Based on the TTM, the Book Value Change Per Share is $-0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.12 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Astellas.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.282.4%0.050.4%0.010.1%0.050.4%0.070.6%0.111.0%
Usd Book Value Change Per Share-0.01-0.1%-0.10-0.9%0.100.8%0.020.2%0.050.4%0.040.3%
Usd Dividend Per Share0.000.0%0.121.1%0.111.0%0.121.0%0.131.1%0.100.9%
Usd Total Gains Per Share-0.01-0.1%0.020.2%0.211.8%0.141.2%0.181.5%0.141.2%
Usd Price Per Share9.66-10.16-12.84-12.52-13.92-14.13-
Price to Earnings Ratio8.62-10.12--140.76--38.96--25.42-182.18-
Price-to-Total Gains Ratio-673.37--151.40-18.54--59.58--6.45-45.16-
Price to Book Ratio1.71-1.74-2.15-2.13-2.53-2.92-
Price-to-Total Gains Ratio-673.37--151.40-18.54--59.58--6.45-45.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.56
Number of shares86
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.120.13
Usd Book Value Change Per Share-0.100.05
Usd Total Gains Per Share0.020.18
Gains per Quarter (86 shares)2.0615.26
Gains per Year (86 shares)8.2461.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
142-34-2451651
284-6869033112
3126-1011413449173
4168-1352217965234
5210-1693022481295
6252-2033826998356
7295-23746314114417
8337-27154358130478
9379-30462403146539
10421-33870448163600

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%8.04.00.066.7%14.06.00.070.0%34.06.00.085.0%53.08.00.086.9%
Book Value Change Per Share1.03.00.025.0%6.06.00.050.0%13.07.00.065.0%27.013.00.067.5%39.020.02.063.9%
Dividend per Share2.00.02.050.0%7.00.05.058.3%15.00.05.075.0%30.00.010.075.0%39.00.022.063.9%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%15.05.00.075.0%31.09.00.077.5%46.015.00.075.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Astellas Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.014-0.098+585%0.097-115%0.022-166%0.047-130%0.040-136%
Book Value Per Share--5.6595.867-4%5.979-5%5.899-4%5.578+1%4.964+14%
Current Ratio--1.1321.045+8%1.032+10%1.167-3%1.269-11%1.653-32%
Debt To Asset Ratio--0.5470.556-2%0.520+5%0.484+13%0.447+22%0.379+44%
Debt To Equity Ratio--1.2071.252-4%1.103+9%0.986+22%0.849+42%0.653+85%
Dividend Per Share---0.122-100%0.110-100%0.116-100%0.130-100%0.101-100%
Enterprise Value--6629700780.0006820233119.505-3%13757239119.188-52%14372438233.252-54%18921734361.710-65%23117441684.782-71%
Eps--0.2800.047+498%0.012+2218%0.050+458%0.075+274%0.114+147%
Ev To Ebitda Ratio--2.3952.500-4%24.981-90%8.677-72%14.156-83%14.277-83%
Ev To Sales Ratio--0.5310.530+0%1.286-59%1.333-60%1.990-73%2.524-79%
Free Cash Flow Per Share--0.3420.148+131%0.092+271%0.156+119%0.175+95%0.188+82%
Free Cash Flow To Equity Per Share--0.002-0.099+4773%0.674-100%0.207-99%0.124-98%0.112-98%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--19.121----------
Intrinsic Value_10Y_min--8.539----------
Intrinsic Value_1Y_max--0.920----------
Intrinsic Value_1Y_min--0.667----------
Intrinsic Value_3Y_max--3.524----------
Intrinsic Value_3Y_min--2.179----------
Intrinsic Value_5Y_max--7.043----------
Intrinsic Value_5Y_min--3.871----------
Market Cap20695983784.960+15%17563937580.00018287096919.505-4%23068338019.188-24%22622316666.585-22%25458446521.710-31%27204350654.782-35%
Net Profit Margin--0.1630.033+396%0.010+1583%0.034+373%0.058+180%0.104+57%
Operating Margin--0.1180.114+3%0.023+412%0.075+57%0.102+15%0.143-18%
Operating Ratio--0.8620.961-10%0.888-3%0.887-3%0.8660%0.839+3%
Pb Ratio2.043+16%1.7071.735-2%2.148-21%2.126-20%2.535-33%2.921-42%
Pe Ratio10.318+16%8.62210.124-15%-140.763+1733%-38.955+552%-25.420+395%182.183-95%
Price Per Share11.560+16%9.66010.158-5%12.843-25%12.520-23%13.922-31%14.128-32%
Price To Free Cash Flow Ratio8.457+16%7.067-102.204+1546%-25.597+462%-36.204+612%-9.400+233%359.467-98%
Price To Total Gains Ratio-805.809-20%-673.366-151.401-78%18.545-3731%-59.579-91%-6.449-99%45.161-1591%
Quick Ratio--0.8300.760+9%0.796+4%0.895-7%0.981-15%1.318-37%
Return On Assets--0.0220.004+516%0.002+1299%0.005+355%0.008+170%0.018+28%
Return On Equity--0.0490.008+559%0.002+2124%0.008+502%0.014+259%0.026+89%
Total Gains Per Share---0.0140.024-160%0.207-107%0.138-110%0.177-108%0.141-110%
Usd Book Value--10290134000.00010562691600.000-3%10738903400.000-4%10651803333.333-3%10171245180.000+1%9473137630.000+9%
Usd Book Value Change Per Share---0.014-0.098+585%0.097-115%0.022-166%0.047-130%0.040-136%
Usd Book Value Per Share--5.6595.867-4%5.979-5%5.899-4%5.578+1%4.964+14%
Usd Dividend Per Share---0.122-100%0.110-100%0.116-100%0.130-100%0.101-100%
Usd Enterprise Value--6629700780.0006820233119.505-3%13757239119.188-52%14372438233.252-54%18921734361.710-65%23117441684.782-71%
Usd Eps--0.2800.047+498%0.012+2218%0.050+458%0.075+274%0.114+147%
Usd Free Cash Flow--621356800.000267765300.000+132%165600400.000+275%281997700.000+120%321363920.000+93%362732910.000+71%
Usd Free Cash Flow Per Share--0.3420.148+131%0.092+271%0.156+119%0.175+95%0.188+82%
Usd Free Cash Flow To Equity Per Share--0.002-0.099+4773%0.674-100%0.207-99%0.124-98%0.112-98%
Usd Market Cap20695983784.960+15%17563937580.00018287096919.505-4%23068338019.188-24%22622316666.585-22%25458446521.710-31%27204350654.782-35%
Usd Price Per Share11.560+16%9.66010.158-5%12.843-25%12.520-23%13.922-31%14.128-32%
Usd Profit--509292800.00086269900.000+490%21938500.000+2221%92007966.667+454%138393940.000+268%238303280.000+114%
Usd Revenue--3123199200.0003250949100.000-4%2726240700.000+15%2852947366.667+9%2577303700.000+21%2409271110.000+30%
Usd Total Gains Per Share---0.0140.024-160%0.207-107%0.138-110%0.177-108%0.141-110%
 EOD+3 -5MRQTTM+23 -16YOY+16 -233Y+14 -255Y+17 -2210Y+17 -22

3.3 Fundamental Score

Let's check the fundamental score of Astellas Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1510.318
Price to Book Ratio (EOD)Between0-12.043
Net Profit Margin (MRQ)Greater than00.163
Operating Margin (MRQ)Greater than00.118
Quick Ratio (MRQ)Greater than10.830
Current Ratio (MRQ)Greater than11.132
Debt to Asset Ratio (MRQ)Less than10.547
Debt to Equity Ratio (MRQ)Less than11.207
Return on Equity (MRQ)Greater than0.150.049
Return on Assets (MRQ)Greater than0.050.022
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Astellas Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.404
Ma 20Greater thanMa 5011.312
Ma 50Greater thanMa 10010.775
Ma 100Greater thanMa 20010.207
OpenGreater thanClose11.640
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Astellas Pharma Inc

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD); EVRENZO, a treatment for anemia associated with chronic kidney disease (CKD); Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressants. The company has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Chuo, Japan.

Fundamental data was last updated by Penke on 2025-09-11 14:48:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Astellas earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 16.3%Β means thatΒ $0.16 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Astellas Pharma Inc:

  • The MRQ is 16.3%. The company is making a huge profit. +2
  • The TTM is 3.3%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ16.3%TTM3.3%+13.0%
TTM3.3%YOY1.0%+2.3%
TTM3.3%5Y5.8%-2.5%
5Y5.8%10Y10.4%-4.5%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Astellas is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • 2.2% Return on Assets means thatΒ Astellas generatedΒ $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Astellas Pharma Inc:

  • The MRQ is 2.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.4%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.2%TTM0.4%+1.9%
TTM0.4%YOY0.2%+0.2%
TTM0.4%5Y0.8%-0.5%
5Y0.8%10Y1.8%-0.9%
4.3.1.3. Return on Equity

Shows how efficient Astellas is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • 4.9% Return on Equity means Astellas generated $0.05Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Astellas Pharma Inc:

  • The MRQ is 4.9%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.9%TTM0.8%+4.2%
TTM0.8%YOY0.2%+0.5%
TTM0.8%5Y1.4%-0.6%
5Y1.4%10Y2.6%-1.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Astellas Pharma Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Astellas is operatingΒ .

  • Measures how much profit Astellas makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • An Operating Margin of 11.8%Β means the company generated $0.12 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Astellas Pharma Inc:

  • The MRQ is 11.8%. The company is operating less efficient.
  • The TTM is 11.4%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ11.8%TTM11.4%+0.3%
TTM11.4%YOY2.3%+9.1%
TTM11.4%5Y10.2%+1.2%
5Y10.2%10Y14.3%-4.1%
4.3.2.2. Operating Ratio

Measures how efficient Astellas is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.86 means that the operating costs are $0.86 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.862. The company is less efficient in keeping operating costs low.
  • The TTM is 0.961. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.862TTM0.961-0.099
TTM0.961YOY0.888+0.073
TTM0.9615Y0.866+0.095
5Y0.86610Y0.839+0.027
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Astellas Pharma Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Astellas is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.13Β means the company has $1.13 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Astellas Pharma Inc:

  • The MRQ is 1.132. The company is just able to pay all its short-term debts.
  • The TTM is 1.045. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.132TTM1.045+0.087
TTM1.045YOY1.032+0.013
TTM1.0455Y1.269-0.224
5Y1.26910Y1.653-0.385
4.4.3.2. Quick Ratio

Measures if Astellas is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.83Β means the company can pay off $0.83 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.830. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.760. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.830TTM0.760+0.070
TTM0.760YOY0.796-0.036
TTM0.7605Y0.981-0.221
5Y0.98110Y1.318-0.337
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Astellas Pharma Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AstellasΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Astellas to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.55Β means that Astellas assets areΒ financed with 54.7% credit (debt) and the remaining percentage (100% - 54.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.547. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.556. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.547TTM0.556-0.009
TTM0.556YOY0.520+0.036
TTM0.5565Y0.447+0.109
5Y0.44710Y0.379+0.068
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Astellas is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 120.7% means that company has $1.21 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Astellas Pharma Inc:

  • The MRQ is 1.207. The company is able to pay all its debts with equity. +1
  • The TTM is 1.252. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.207TTM1.252-0.045
TTM1.252YOY1.103+0.149
TTM1.2525Y0.849+0.403
5Y0.84910Y0.653+0.196
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Astellas generates.

  • Above 15 is considered overpriced butΒ always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • A PE ratio of 8.62 means the investor is paying $8.62Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Astellas Pharma Inc:

  • The EOD is 10.318. Based on the earnings, the company is underpriced. +1
  • The MRQ is 8.622. Based on the earnings, the company is underpriced. +1
  • The TTM is 10.124. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD10.318MRQ8.622+1.696
MRQ8.622TTM10.124-1.503
TTM10.124YOY-140.763+150.888
TTM10.1245Y-25.420+35.544
5Y-25.42010Y182.183-207.603
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Astellas Pharma Inc:

  • The EOD is 8.457. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 7.067. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -102.204. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD8.457MRQ7.067+1.390
MRQ7.067TTM-102.204+109.271
TTM-102.204YOY-25.597-76.608
TTM-102.2045Y-9.400-92.805
5Y-9.40010Y359.467-368.866
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Astellas is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 1.71 means the investor is paying $1.71Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Astellas Pharma Inc:

  • The EOD is 2.043. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.707. Based on the equity, the company is underpriced. +1
  • The TTM is 1.735. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.043MRQ1.707+0.336
MRQ1.707TTM1.735-0.028
TTM1.735YOY2.148-0.412
TTM1.7355Y2.535-0.799
5Y2.53510Y2.921-0.386
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in JPY. All numbers in thousands.

Summary
Total Assets3,339,544,000
Total Liabilities1,826,289,000
Total Stockholder Equity1,513,255,000
 As reported
Total Liabilities 1,826,289,000
Total Stockholder Equity+ 1,513,255,000
Total Assets = 3,339,544,000

Assets

Total Assets3,339,544,000
Total Current Assets1,201,349,000
Long-term Assets2,138,195,000
Total Current Assets
Cash And Cash Equivalents 188,372,000
Short-term Investments 29,941,000
Net Receivables 632,525,000
Inventory 297,261,000
Other Current Assets 53,250,000
Total Current Assets  (as reported)1,201,349,000
Total Current Assets  (calculated)1,201,349,000
+/-0
Long-term Assets
Property Plant Equipment 328,921,000
Goodwill 415,207,000
Intangible Assets 1,123,714,000
Long-term Assets Other 153,251,000
Long-term Assets  (as reported)2,138,195,000
Long-term Assets  (calculated)2,021,093,000
+/- 117,102,000

Liabilities & Shareholders' Equity

Total Current Liabilities1,061,610,000
Long-term Liabilities764,679,000
Total Stockholder Equity1,513,255,000
Total Current Liabilities
Short-term Debt 266,533,000
Short Long Term Debt 266,533,000
Accounts payable 187,840,000
Other Current Liabilities 572,688,000
Total Current Liabilities  (as reported)1,061,610,000
Total Current Liabilities  (calculated)1,293,594,000
+/- 231,984,000
Long-term Liabilities
Long term Debt 564,893,000
Long-term Liabilities Other 53,568,000
Long-term Liabilities  (as reported)764,679,000
Long-term Liabilities  (calculated)618,461,000
+/- 146,218,000
Total Stockholder Equity
Common Stock103,001,000
Retained Earnings 740,939,000
Other Stockholders Equity 669,315,000
Total Stockholder Equity (as reported)1,513,255,000
Total Stockholder Equity (calculated)1,513,255,000
+/-0
Other
Capital Stock103,001,000
Cash and Short Term Investments 218,313,000
Common Stock Shares Outstanding 1,818,213
Liabilities and Stockholders Equity 3,339,544,000
Net Debt 643,054,000
Net Invested Capital 2,344,681,000
Net Working Capital 139,739,000
Short Long Term Debt Total 831,426,000



6.2. Balance Sheets Structured

Currency in JPY. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-30
> Total Assets 
0
0
1,348,446,000
0
1,386,961,000
1,362,910,000
1,364,176,000
1,341,307,000
1,355,246,000
1,302,318,000
1,335,091,000
1,351,736,000
1,326,941,000
1,358,841,000
1,400,629,000
1,336,129,000
1,319,494,000
1,418,079,000
1,445,561,000
1,471,067,000
1,497,122,000
1,565,175,000
1,653,108,000
1,616,276,000
1,715,340,000
1,851,850,000
1,793,578,000
1,780,003,000
1,770,678,000
1,787,802,000
1,799,338,000
1,693,626,000
1,713,181,000
1,853,939,000
1,820,901,000
1,901,237,000
1,895,713,000
1,933,831,000
1,858,205,000
1,866,551,000
1,886,926,000
1,928,325,000
1,897,648,000
1,927,031,000
1,979,816,000
1,989,779,000
2,318,160,000
2,256,035,000
2,237,016,000
2,296,843,000
2,273,628,000
2,249,456,000
2,261,508,000
2,356,245,000
2,332,395,000
2,481,843,000
2,583,661,000
2,513,948,000
2,456,518,000
2,797,958,000
3,543,021,000
3,368,682,000
3,569,603,000
3,735,514,000
3,462,237,000
3,451,630,000
3,339,544,000
3,339,544,0003,451,630,0003,462,237,0003,735,514,0003,569,603,0003,368,682,0003,543,021,0002,797,958,0002,456,518,0002,513,948,0002,583,661,0002,481,843,0002,332,395,0002,356,245,0002,261,508,0002,249,456,0002,273,628,0002,296,843,0002,237,016,0002,256,035,0002,318,160,0001,989,779,0001,979,816,0001,927,031,0001,897,648,0001,928,325,0001,886,926,0001,866,551,0001,858,205,0001,933,831,0001,895,713,0001,901,237,0001,820,901,0001,853,939,0001,713,181,0001,693,626,0001,799,338,0001,787,802,0001,770,678,0001,780,003,0001,793,578,0001,851,850,0001,715,340,0001,616,276,0001,653,108,0001,565,175,0001,497,122,0001,471,067,0001,445,561,0001,418,079,0001,319,494,0001,336,129,0001,400,629,0001,358,841,0001,326,941,0001,351,736,0001,335,091,0001,302,318,0001,355,246,0001,341,307,0001,364,176,0001,362,910,0001,386,961,00001,348,446,00000
   > Total Current Assets 
0
0
963,640,000
0
1,003,593,000
986,898,000
988,544,000
696,408,000
664,227,000
632,328,000
653,154,000
689,022,000
742,782,000
773,246,000
781,078,000
741,439,000
731,215,000
801,648,000
827,190,000
846,077,000
884,340,000
945,067,000
913,292,000
891,055,000
966,361,000
1,041,886,000
965,958,000
955,231,000
953,576,000
912,122,000
897,537,000
838,927,000
874,694,000
900,763,000
876,665,000
875,921,000
870,173,000
925,200,000
845,619,000
844,734,000
845,514,000
890,258,000
857,159,000
820,130,000
855,596,000
834,150,000
867,514,000
795,979,000
819,902,000
863,294,000
872,588,000
868,715,000
876,454,000
939,331,000
923,354,000
989,281,000
1,059,145,000
1,072,593,000
1,049,954,000
1,317,454,000
1,116,756,000
1,050,102,000
1,194,730,000
1,240,664,000
1,203,009,000
1,203,913,000
1,201,349,000
1,201,349,0001,203,913,0001,203,009,0001,240,664,0001,194,730,0001,050,102,0001,116,756,0001,317,454,0001,049,954,0001,072,593,0001,059,145,000989,281,000923,354,000939,331,000876,454,000868,715,000872,588,000863,294,000819,902,000795,979,000867,514,000834,150,000855,596,000820,130,000857,159,000890,258,000845,514,000844,734,000845,619,000925,200,000870,173,000875,921,000876,665,000900,763,000874,694,000838,927,000897,537,000912,122,000953,576,000955,231,000965,958,0001,041,886,000966,361,000891,055,000913,292,000945,067,000884,340,000846,077,000827,190,000801,648,000731,215,000741,439,000781,078,000773,246,000742,782,000689,022,000653,154,000632,328,000664,227,000696,408,000988,544,000986,898,0001,003,593,0000963,640,00000
       Cash And Cash Equivalents 
0
0
267,460,000
0
276,578,000
279,168,000
312,196,000
199,220,000
184,142,000
140,541,000
142,895,000
166,017,000
206,353,000
216,446,000
210,986,000
189,662,000
191,520,000
242,967,000
264,912,000
234,565,000
258,659,000
303,437,000
391,374,000
373,015,000
421,345,000
438,008,000
396,430,000
371,537,000
388,136,000
340,454,000
360,030,000
311,985,000
366,325,000
348,660,000
340,923,000
314,417,000
307,923,000
331,683,000
331,731,000
309,741,000
306,867,000
331,296,000
311,074,000
259,422,000
311,367,000
277,602,000
318,391,000
239,934,000
286,734,000
306,514,000
326,128,000
301,920,000
318,295,000
350,213,000
315,986,000
313,013,000
361,073,000
381,816,000
376,840,000
561,487,000
333,993,000
253,978,000
335,687,000
302,928,000
292,993,000
179,865,000
188,372,000
188,372,000179,865,000292,993,000302,928,000335,687,000253,978,000333,993,000561,487,000376,840,000381,816,000361,073,000313,013,000315,986,000350,213,000318,295,000301,920,000326,128,000306,514,000286,734,000239,934,000318,391,000277,602,000311,367,000259,422,000311,074,000331,296,000306,867,000309,741,000331,731,000331,683,000307,923,000314,417,000340,923,000348,660,000366,325,000311,985,000360,030,000340,454,000388,136,000371,537,000396,430,000438,008,000421,345,000373,015,000391,374,000303,437,000258,659,000234,565,000264,912,000242,967,000191,520,000189,662,000210,986,000216,446,000206,353,000166,017,000142,895,000140,541,000184,142,000199,220,000312,196,000279,168,000276,578,0000267,460,00000
       Short-term Investments 
0
0
246,463,000
0
266,367,000
213,176,000
225,078,000
45,597,000
22,189,000
19,594,000
33,908,000
46,204,000
75,543,000
64,970,000
88,112,000
70,816,000
66,065,000
40,622,000
47,765,000
85,770,000
89,242,000
66,370,000
35,406,000
33,260,000
42,162,000
37,651,000
59,908,000
44,135,000
28,789,000
21,749,000
14,394,000
12,726,000
11,982,000
22,666,000
13,554,000
32,086,000
47,475,000
61,549,000
13,517,000
23,702,000
28,501,000
21,877,000
2,607,000
3,934,000
19,957,000
4,538,000
9,459,000
4,590,000
7,703,000
19,967,000
5,560,000
4,075,000
9,993,000
17,880,000
21,297,000
23,746,000
31,947,000
31,480,000
19,784,000
41,326,000
29,656,000
31,458,000
28,784,000
0
36,264,000
0
29,941,000
29,941,000036,264,000028,784,00031,458,00029,656,00041,326,00019,784,00031,480,00031,947,00023,746,00021,297,00017,880,0009,993,0004,075,0005,560,00019,967,0007,703,0004,590,0009,459,0004,538,00019,957,0003,934,0002,607,00021,877,00028,501,00023,702,00013,517,00061,549,00047,475,00032,086,00013,554,00022,666,00011,982,00012,726,00014,394,00021,749,00028,789,00044,135,00059,908,00037,651,00042,162,00033,260,00035,406,00066,370,00089,242,00085,770,00047,765,00040,622,00066,065,00070,816,00088,112,00064,970,00075,543,00046,204,00033,908,00019,594,00022,189,00045,597,000225,078,000213,176,000266,367,0000246,463,00000
       Net Receivables 
0
0
290,546,000
0
228,402,000
262,775,000
291,404,000
239,130,000
250,556,000
274,178,000
330,315,000
260,382,000
261,820,000
295,930,000
336,236,000
267,568,000
263,266,000
291,871,000
300,121,000
283,547,000
287,011,000
319,001,000
332,639,000
324,044,000
333,571,000
394,962,000
332,923,000
360,568,000
351,233,000
376,311,000
327,599,000
336,070,000
316,187,000
347,939,000
309,817,000
337,599,000
314,065,000
347,940,000
319,512,000
333,509,000
323,101,000
347,125,000
342,628,000
358,800,000
335,773,000
366,940,000
347,042,000
360,717,000
332,732,000
345,605,000
343,178,000
364,233,000
357,801,000
373,923,000
382,462,000
438,413,000
452,485,000
451,275,000
427,965,000
462,503,000
487,893,000
495,961,000
534,985,000
587,667,000
558,269,000
644,633,000
632,525,000
632,525,000644,633,000558,269,000587,667,000534,985,000495,961,000487,893,000462,503,000427,965,000451,275,000452,485,000438,413,000382,462,000373,923,000357,801,000364,233,000343,178,000345,605,000332,732,000360,717,000347,042,000366,940,000335,773,000358,800,000342,628,000347,125,000323,101,000333,509,000319,512,000347,940,000314,065,000337,599,000309,817,000347,939,000316,187,000336,070,000327,599,000376,311,000351,233,000360,568,000332,923,000394,962,000333,571,000324,044,000332,639,000319,001,000287,011,000283,547,000300,121,000291,871,000263,266,000267,568,000336,236,000295,930,000261,820,000260,382,000330,315,000274,178,000250,556,000239,130,000291,404,000262,775,000228,402,0000290,546,00000
       Other Current Assets 
0
0
53,742,000
0
120,845,000
119,964,000
48,814,000
98,903,000
89,839,000
87,458,000
29,156,000
101,343,000
90,380,000
88,862,000
33,923,000
99,292,000
361,513,000
106,003,000
86,212,000
103,518,000
101,519,000
112,026,000
18,645,000
16,005,000
14,639,000
17,947,000
19,790,000
21,304,000
26,285,000
24,971,000
33,823,000
19,927,000
22,755,000
21,624,000
29,834,000
23,547,000
38,012,000
37,767,000
33,233,000
32,189,000
37,959,000
44,793,000
49,339,000
47,435,000
40,463,000
35,794,000
41,605,000
35,665,000
36,995,000
35,465,000
39,202,000
45,308,000
51,626,000
63,619,000
71,834,000
73,027,000
76,951,000
76,281,000
70,763,000
93,240,000
81,222,000
74,183,000
75,320,000
94,024,000
55,269,000
92,072,000
53,250,000
53,250,00092,072,00055,269,00094,024,00075,320,00074,183,00081,222,00093,240,00070,763,00076,281,00076,951,00073,027,00071,834,00063,619,00051,626,00045,308,00039,202,00035,465,00036,995,00035,665,00041,605,00035,794,00040,463,00047,435,00049,339,00044,793,00037,959,00032,189,00033,233,00037,767,00038,012,00023,547,00029,834,00021,624,00022,755,00019,927,00033,823,00024,971,00026,285,00021,304,00019,790,00017,947,00014,639,00016,005,00018,645,000112,026,000101,519,000103,518,00086,212,000106,003,000361,513,00099,292,00033,923,00088,862,00090,380,000101,343,00029,156,00087,458,00089,839,00098,903,00048,814,000119,964,000120,845,000053,742,00000
   > Long-term Assets 
0
0
384,806,000
0
383,368,000
376,012,000
375,632,000
644,899,000
691,019,000
669,990,000
681,937,000
662,714,000
584,159,000
585,595,000
619,551,000
594,690,000
588,277,000
616,429,000
618,371,000
624,990,000
612,782,000
620,108,000
739,816,000
725,221,000
748,979,000
809,964,000
827,620,000
824,772,000
817,102,000
875,680,000
901,801,000
854,699,000
838,487,000
953,176,000
944,236,000
1,025,316,000
1,025,540,000
1,008,631,000
1,012,586,000
1,021,817,000
1,041,412,000
1,038,067,000
1,040,489,000
1,106,901,000
1,124,220,000
1,155,629,000
1,450,646,000
1,460,056,000
1,417,114,000
1,433,549,000
1,401,040,000
1,380,741,000
1,385,054,000
1,416,914,000
1,409,041,000
1,492,562,000
1,524,516,000
1,441,355,000
1,406,564,000
1,480,504,000
2,426,265,000
2,318,580,000
2,374,873,000
2,494,850,000
2,259,229,000
2,247,717,000
2,138,195,000
2,138,195,0002,247,717,0002,259,229,0002,494,850,0002,374,873,0002,318,580,0002,426,265,0001,480,504,0001,406,564,0001,441,355,0001,524,516,0001,492,562,0001,409,041,0001,416,914,0001,385,054,0001,380,741,0001,401,040,0001,433,549,0001,417,114,0001,460,056,0001,450,646,0001,155,629,0001,124,220,0001,106,901,0001,040,489,0001,038,067,0001,041,412,0001,021,817,0001,012,586,0001,008,631,0001,025,540,0001,025,316,000944,236,000953,176,000838,487,000854,699,000901,801,000875,680,000817,102,000824,772,000827,620,000809,964,000748,979,000725,221,000739,816,000620,108,000612,782,000624,990,000618,371,000616,429,000588,277,000594,690,000619,551,000585,595,000584,159,000662,714,000681,937,000669,990,000691,019,000644,899,000375,632,000376,012,000383,368,0000384,806,00000
       Property Plant Equipment 
0
0
181,447,000
0
184,574,000
184,020,000
184,489,000
191,598,000
186,609,000
185,017,000
190,160,000
191,130,000
189,530,000
190,408,000
199,159,000
195,223,000
199,663,000
207,910,000
218,479,000
218,139,000
218,974,000
223,740,000
191,451,000
188,223,000
192,816,000
205,932,000
202,869,000
205,520,000
203,708,000
202,432,000
200,955,000
192,135,000
182,726,000
188,714,000
191,115,000
193,665,000
182,697,000
184,332,000
181,295,000
179,769,000
183,309,000
174,798,000
173,483,000
251,898,000
254,707,000
260,902,000
268,600,000
267,107,000
265,670,000
255,178,000
264,623,000
269,698,000
266,671,000
267,817,000
269,044,000
280,179,000
280,552,000
269,106,000
286,459,000
290,784,000
296,555,000
289,029,000
293,742,000
309,686,000
315,345,000
332,724,000
328,921,000
328,921,000332,724,000315,345,000309,686,000293,742,000289,029,000296,555,000290,784,000286,459,000269,106,000280,552,000280,179,000269,044,000267,817,000266,671,000269,698,000264,623,000255,178,000265,670,000267,107,000268,600,000260,902,000254,707,000251,898,000173,483,000174,798,000183,309,000179,769,000181,295,000184,332,000182,697,000193,665,000191,115,000188,714,000182,726,000192,135,000200,955,000202,432,000203,708,000205,520,000202,869,000205,932,000192,816,000188,223,000191,451,000223,740,000218,974,000218,139,000218,479,000207,910,000199,663,000195,223,000199,159,000190,408,000189,530,000191,130,000190,160,000185,017,000186,609,000191,598,000184,489,000184,020,000184,574,0000181,447,00000
       Goodwill 
0
0
26,377,000
0
20,993,000
21,166,000
22,159,000
267,992,000
105,620,000
103,313,000
101,255,000
101,667,000
93,590,000
92,025,000
94,192,000
88,033,000
83,326,000
89,706,000
95,978,000
99,110,000
95,957,000
101,913,000
116,766,000
114,996,000
124,175,000
136,768,000
136,337,000
138,924,000
136,099,000
136,836,000
150,660,000
139,661,000
137,232,000
187,267,000
175,350,000
203,291,000
199,053,000
192,547,000
212,976,000
219,240,000
226,402,000
226,588,000
225,864,000
220,129,000
219,365,000
226,924,000
267,510,000
276,874,000
273,395,000
267,796,000
284,011,000
284,114,000
284,993,000
293,649,000
303,030,000
334,260,000
353,095,000
324,068,000
328,411,000
355,683,000
403,822,000
387,969,000
418,694,000
443,674,000
399,436,000
432,795,000
415,207,000
415,207,000432,795,000399,436,000443,674,000418,694,000387,969,000403,822,000355,683,000328,411,000324,068,000353,095,000334,260,000303,030,000293,649,000284,993,000284,114,000284,011,000267,796,000273,395,000276,874,000267,510,000226,924,000219,365,000220,129,000225,864,000226,588,000226,402,000219,240,000212,976,000192,547,000199,053,000203,291,000175,350,000187,267,000137,232,000139,661,000150,660,000136,836,000136,099,000138,924,000136,337,000136,768,000124,175,000114,996,000116,766,000101,913,00095,957,00099,110,00095,978,00089,706,00083,326,00088,033,00094,192,00092,025,00093,590,000101,667,000101,255,000103,313,000105,620,000267,992,00022,159,00021,166,00020,993,000026,377,00000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
130,731,000
123,303,000
126,579,000
117,328,000
100,003,000
98,360,000
980,251
129,051,279
1,811,049
138,042,365
1,889,398
109,505,000
118,479,000
120,285,000
125,842,000
127,455,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000127,455,000125,842,000120,285,000118,479,000109,505,0001,889,398138,042,3651,811,049129,051,279980,25198,360,000100,003,000117,328,000126,579,000123,303,000130,731,000000000000000000000000000000000
       Intangible Assets 
0
0
31,984,000
0
40,495,000
41,808,000
40,601,000
37,787,000
277,307,000
258,415,000
265,922,000
254,199,000
189,040,000
190,115,000
220,085,000
206,365,000
200,082,000
213,011,000
198,864,000
200,149,000
187,468,000
177,624,000
280,120,000
269,019,000
278,238,000
301,156,000
295,844,000
288,245,000
285,656,000
331,764,000
339,202,000
319,620,000
317,754,000
380,522,000
387,419,000
435,142,000
433,413,000
428,018,000
416,912,000
408,998,000
411,140,000
432,884,000
429,707,000
423,704,000
432,338,000
455,406,000
738,507,000
729,400,000
687,306,000
697,164,000
935,438,000
630,322,000
640,981,000
652,251,000
623,431,000
639,834,000
653,629,000
616,538,000
562,496,000
590,424,000
1,532,551,000
1,452,341,000
1,453,824,000
1,503,157,000
1,321,601,000
1,211,344,000
1,123,714,000
1,123,714,0001,211,344,0001,321,601,0001,503,157,0001,453,824,0001,452,341,0001,532,551,000590,424,000562,496,000616,538,000653,629,000639,834,000623,431,000652,251,000640,981,000630,322,000935,438,000697,164,000687,306,000729,400,000738,507,000455,406,000432,338,000423,704,000429,707,000432,884,000411,140,000408,998,000416,912,000428,018,000433,413,000435,142,000387,419,000380,522,000317,754,000319,620,000339,202,000331,764,000285,656,000288,245,000295,844,000301,156,000278,238,000269,019,000280,120,000177,624,000187,468,000200,149,000198,864,000213,011,000200,082,000206,365,000220,085,000190,115,000189,040,000254,199,000265,922,000258,415,000277,307,00037,787,00040,601,00041,808,00040,495,000031,984,00000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000
2,000
42,442,000
0
1,000
2,000
45,531,000
50,797,000
50,857,000
44,697,000
51,199,000
51,972,000
60,091,000
58,675,000
80,253,000
79,980,000
74,196,000
79,345,000
90,349,000
94,858,000
99,839,000
96,273,000
97,236,000
95,204,000
97,732,000
94,292,000
92,956,000
90,885,000
91,968,000
84,942,000
52,875,000
55,487,000
55,231,000
51,514,000
54,175,000
54,556,000
55,089,000
58,456,000
72,330,000
92,101,000
96,461,000
93,226,000
84,170,000
100,641,000
0
0
0
0
-1,000
0
0
00-1,0000000100,641,00084,170,00093,226,00096,461,00092,101,00072,330,00058,456,00055,089,00054,556,00054,175,00051,514,00055,231,00055,487,00052,875,00084,942,00091,968,00090,885,00092,956,00094,292,00097,732,00095,204,00097,236,00096,273,00099,839,00094,858,00090,349,00079,345,00074,196,00079,980,00080,253,00058,675,00060,091,00051,972,00051,199,00044,697,00050,857,00050,797,00045,531,0002,0001,000042,442,0002,0002,0000000000000000000
> Total Liabilities 
0
0
318,225,000
0
307,659,000
302,019,000
310,243,000
329,134,000
336,237,000
298,207,000
313,995,000
346,190,000
346,780,000
365,198,000
382,506,000
352,043,000
253,263,000
295,690,000
383,535,000
317,154,000
307,656,000
340,935,000
384,632,000
386,426,000
420,159,000
477,664,000
475,662,000
446,207,000
447,587,000
465,508,000
540,129,000
503,099,000
485,928,000
540,387,000
549,091,000
581,585,000
544,806,000
566,967,000
589,916,000
590,630,000
604,241,000
636,116,000
639,252,000
677,323,000
683,681,000
672,333,000
1,028,992,000
949,351,000
907,388,000
928,234,000
887,514,000
866,587,000
843,886,000
889,953,000
872,086,000
942,790,000
934,142,000
943,524,000
948,564,000
1,219,542,000
1,903,676,000
1,865,428,000
1,973,616,000
2,059,072,000
1,932,395,000
1,957,821,000
1,826,289,000
1,826,289,0001,957,821,0001,932,395,0002,059,072,0001,973,616,0001,865,428,0001,903,676,0001,219,542,000948,564,000943,524,000934,142,000942,790,000872,086,000889,953,000843,886,000866,587,000887,514,000928,234,000907,388,000949,351,0001,028,992,000672,333,000683,681,000677,323,000639,252,000636,116,000604,241,000590,630,000589,916,000566,967,000544,806,000581,585,000549,091,000540,387,000485,928,000503,099,000540,129,000465,508,000447,587,000446,207,000475,662,000477,664,000420,159,000386,426,000384,632,000340,935,000307,656,000317,154,000383,535,000295,690,000253,263,000352,043,000382,506,000365,198,000346,780,000346,190,000313,995,000298,207,000336,237,000329,134,000310,243,000302,019,000307,659,0000318,225,00000
   > Total Current Liabilities 
0
0
283,553,000
0
277,865,000
271,475,000
277,157,000
283,152,000
261,863,000
228,966,000
239,648,000
273,563,000
275,982,000
307,370,000
314,170,000
288,173,000
253,263,000
295,690,000
313,536,000
317,154,000
307,656,000
340,935,000
340,688,000
341,699,000
375,105,000
424,429,000
420,890,000
391,225,000
395,225,000
409,640,000
413,359,000
396,568,000
383,527,000
400,061,000
399,856,000
401,050,000
365,396,000
395,628,000
421,620,000
438,647,000
447,580,000
494,592,000
495,759,000
464,162,000
483,626,000
466,058,000
798,708,000
647,672,000
616,933,000
635,847,000
592,372,000
581,580,000
554,768,000
597,976,000
687,411,000
740,538,000
761,412,000
705,905,000
726,034,000
991,494,000
1,162,259,000
1,153,715,000
1,285,725,000
1,373,811,000
1,093,355,000
1,152,557,000
1,061,610,000
1,061,610,0001,152,557,0001,093,355,0001,373,811,0001,285,725,0001,153,715,0001,162,259,000991,494,000726,034,000705,905,000761,412,000740,538,000687,411,000597,976,000554,768,000581,580,000592,372,000635,847,000616,933,000647,672,000798,708,000466,058,000483,626,000464,162,000495,759,000494,592,000447,580,000438,647,000421,620,000395,628,000365,396,000401,050,000399,856,000400,061,000383,527,000396,568,000413,359,000409,640,000395,225,000391,225,000420,890,000424,429,000375,105,000341,699,000340,688,000340,935,000307,656,000317,154,000313,536,000295,690,000253,263,000288,173,000314,170,000307,370,000275,982,000273,563,000239,648,000228,966,000261,863,000283,152,000277,157,000271,475,000277,865,0000283,553,00000
       Short-term Debt 
0
0
0
0
0
0
0
54,991,000
30,000,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,826,000
1,158,000
869,000
842,000
2,075,000
3,768,000
33,344
4,516,633
84,548
0
0
0
0
0
0
0
326,000,000
0
0
0
136,101,000
0
0
0
157,730,000
0
0
0
75,000,000
309,000,000
416,558,000
407,177,000
487,222,000
549,596,000
307,257,000
329,853,000
266,533,000
266,533,000329,853,000307,257,000549,596,000487,222,000407,177,000416,558,000309,000,00075,000,000000157,730,000000136,101,000000326,000,000000000084,5484,516,63333,3443,768,0002,075,000842,000869,0001,158,0002,826,00000000000000000000000030,000,00054,991,0000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,826,000
1,158,000
869,000
842,000
2,075,000
3,768,000
33,344
4,516,633
84,548
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75,000,000
309,000,000
416,558,000
407,177,000
472,278,000
0
307,257,000
0
266,533,000
266,533,0000307,257,0000472,278,000407,177,000416,558,000309,000,00075,000,000000000000000000000084,5484,516,63333,3443,768,0002,075,000842,000869,0001,158,0002,826,000000000000000000000000000000000
       Accounts payable 
0
0
181,561,000
0
87,090,000
100,400,000
177,988,000
93,736,000
93,042,000
98,212,000
139,232,000
97,292,000
94,206,000
114,307,000
190,795,000
103,744,000
87,869,000
115,668,000
201,762,000
106,638,000
108,381,000
114,910,000
187,032,000
185,394,000
212,822,000
220,063,000
226,602,000
199,513,000
202,021,000
199,145,000
181,559,000
158,790,000
154,127,000
162,234,000
182,826,000
152,683,000
125,118,000
137,899,000
140,909,000
138,123,000
145,832,000
191,627,000
185,280,000
140,035,000
160,333,000
139,856,000
171,954,000
132,649,000
113,511,000
111,000,000
124,777,000
108,453,000
111,568,000
136,892,000
130,739,000
152,220,000
146,533,000
134,235,000
140,236,000
138,439,000
147,250,000
150,426,000
185,193,000
1,076,377
161,167,000
204,305,000
187,840,000
187,840,000204,305,000161,167,0001,076,377185,193,000150,426,000147,250,000138,439,000140,236,000134,235,000146,533,000152,220,000130,739,000136,892,000111,568,000108,453,000124,777,000111,000,000113,511,000132,649,000171,954,000139,856,000160,333,000140,035,000185,280,000191,627,000145,832,000138,123,000140,909,000137,899,000125,118,000152,683,000182,826,000162,234,000154,127,000158,790,000181,559,000199,145,000202,021,000199,513,000226,602,000220,063,000212,822,000185,394,000187,032,000114,910,000108,381,000106,638,000201,762,000115,668,00087,869,000103,744,000190,795,000114,307,00094,206,00097,292,000139,232,00098,212,00093,042,00093,736,000177,988,000100,400,00087,090,0000181,561,00000
       Other Current Liabilities 
0
0
101,992,000
0
190,775,000
171,075,000
99,169,000
117,655,000
120,605,000
130,754,000
100,416,000
176,271,000
181,776,000
193,063,000
123,375,000
184,429,000
165,394,000
180,022,000
111,774,000
210,516,000
199,275,000
226,025,000
153,656,000
156,305,000
162,283,000
204,366,000
194,288,000
191,712,000
193,204,000
210,495,000
231,800,000
237,778,000
229,400,000
237,827,000
217,030,000
248,367,000
240,278,000
257,729,000
280,711,000
300,524,000
301,748,000
302,965,000
310,479,000
324,127,000
323,293,000
326,202,000
300,754,000
515,023,000
503,422,000
524,847,000
323,099,000
458,493,000
430,819,000
439,101,000
366,554,000
569,459,000
588,633,000
553,221,000
505,661,000
527,784,000
567,127,000
561,290,000
574,795,000
621,566,552
588,886,000
618,399,000
572,688,000
572,688,000618,399,000588,886,000621,566,552574,795,000561,290,000567,127,000527,784,000505,661,000553,221,000588,633,000569,459,000366,554,000439,101,000430,819,000458,493,000323,099,000524,847,000503,422,000515,023,000300,754,000326,202,000323,293,000324,127,000310,479,000302,965,000301,748,000300,524,000280,711,000257,729,000240,278,000248,367,000217,030,000237,827,000229,400,000237,778,000231,800,000210,495,000193,204,000191,712,000194,288,000204,366,000162,283,000156,305,000153,656,000226,025,000199,275,000210,516,000111,774,000180,022,000165,394,000184,429,000123,375,000193,063,000181,776,000176,271,000100,416,000130,754,000120,605,000117,655,00099,169,000171,075,000190,775,0000101,992,00000
   > Long-term Liabilities 
0
0
34,672,000
0
29,794,000
30,544,000
33,086,000
45,982,000
74,374,000
69,241,000
74,347,000
72,627,000
70,798,000
57,828,000
68,336,000
63,870,000
62,932,000
71,164,000
69,999,000
64,625,000
66,819,000
63,870,000
43,944,000
44,727,000
45,054,000
53,235,000
54,772,000
54,982,000
52,362,000
55,868,000
126,770,000
106,531,000
102,401,000
140,326,000
149,235,000
180,535,000
179,410,000
171,339,000
168,296,000
151,983,000
156,661,000
141,524,000
143,493,000
213,161,000
200,055,000
206,275,000
230,284,000
301,679,000
290,455,000
292,387,000
295,142,000
285,007,000
289,118,000
291,977,000
184,675,000
202,252,000
172,730,000
237,619,000
222,530,000
228,048,000
741,417,000
711,713,000
687,891,000
685,261,000
839,040,000
805,264,000
764,679,000
764,679,000805,264,000839,040,000685,261,000687,891,000711,713,000741,417,000228,048,000222,530,000237,619,000172,730,000202,252,000184,675,000291,977,000289,118,000285,007,000295,142,000292,387,000290,455,000301,679,000230,284,000206,275,000200,055,000213,161,000143,493,000141,524,000156,661,000151,983,000168,296,000171,339,000179,410,000180,535,000149,235,000140,326,000102,401,000106,531,000126,770,00055,868,00052,362,00054,982,00054,772,00053,235,00045,054,00044,727,00043,944,00063,870,00066,819,00064,625,00069,999,00071,164,00062,932,00063,870,00068,336,00057,828,00070,798,00072,627,00074,347,00069,241,00074,374,00045,982,00033,086,00030,544,00029,794,000034,672,00000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
147,659,000
176,767,000
1,557,664
201,246,547
2,849,168
172,813,082
2,350,253
139,952,000
141,152,000
211,564,000
197,089,000
203,122,000
157,915,000
298,857,000
287,707,000
291,141,000
152,578,000
284,699,000
288,674,000
291,314,000
128,986,000
197,383,000
167,708,000
233,241,000
106,852,000
175,679,000
0
0
0
0
0
0
0
0000000175,679,000106,852,000233,241,000167,708,000197,383,000128,986,000291,314,000288,674,000284,699,000152,578,000291,141,000287,707,000298,857,000157,915,000203,122,000197,089,000211,564,000141,152,000139,952,0002,350,253172,813,0822,849,168201,246,5471,557,664176,767,000147,659,0000000000000000000000000000000000000
> Total Stockholder Equity
0
0
1,029,883,000
0
1,079,002,000
1,060,570,000
1,053,581,000
1,012,173,000
1,019,009,000
1,004,111,000
1,021,096,000
1,005,546,000
980,161,000
993,643,000
1,018,123,000
984,086,000
1,025,107,000
1,051,226,000
1,062,026,000
1,089,288,000
1,122,647,000
1,160,371,000
1,268,476,000
1,229,850,000
1,295,181,000
1,374,186,000
1,317,916,000
1,333,796,000
1,323,091,000
1,322,294,000
1,259,209,000
1,190,527,000
1,227,253,000
1,313,552,000
1,271,810,000
1,319,652,000
1,350,907,000
1,366,864,000
1,268,289,000
1,275,921,000
1,282,685,000
1,292,209,000
1,258,396,000
1,249,708,000
1,296,135,000
1,317,446,000
1,289,168,000
1,306,684,000
1,329,628,000
1,368,609,000
1,386,115,000
1,382,869,000
1,417,622,000
1,466,291,000
1,460,308,000
1,539,052,000
1,649,518,000
1,570,424,000
1,507,954,000
1,578,417,000
1,639,345,000
1,503,255,000
1,595,988,000
1,676,442,000
1,529,842,000
1,493,809,000
1,513,255,000
1,513,255,0001,493,809,0001,529,842,0001,676,442,0001,595,988,0001,503,255,0001,639,345,0001,578,417,0001,507,954,0001,570,424,0001,649,518,0001,539,052,0001,460,308,0001,466,291,0001,417,622,0001,382,869,0001,386,115,0001,368,609,0001,329,628,0001,306,684,0001,289,168,0001,317,446,0001,296,135,0001,249,708,0001,258,396,0001,292,209,0001,282,685,0001,275,921,0001,268,289,0001,366,864,0001,350,907,0001,319,652,0001,271,810,0001,313,552,0001,227,253,0001,190,527,0001,259,209,0001,322,294,0001,323,091,0001,333,796,0001,317,916,0001,374,186,0001,295,181,0001,229,850,0001,268,476,0001,160,371,0001,122,647,0001,089,288,0001,062,026,0001,051,226,0001,025,107,000984,086,0001,018,123,000993,643,000980,161,0001,005,546,0001,021,096,0001,004,111,0001,019,009,0001,012,173,0001,053,581,0001,060,570,0001,079,002,00001,029,883,00000
   Common Stock
0
0
103,000,000
0
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,000,000
103,001,000
103,000,000
103,000,000
103,000,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,000,000103,000,000103,000,000103,001,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,000103,000,0000103,000,00000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-63,023,000
-28,638,000
-21,382,000
42,341,000
178,358,000
164,552,000
194,396,000
262,429,000
220,007,000
245,999,000
220,002,000
219,466,000
163,362,000
64,169,000
53,396,000
155,734,000
116,002,000
155,658,000
195,762,000
207,460,000
147,944,000
164,088,000
193,751,000
153,673,000
150,766,000
119,821,000
96,786,000
129,746,000
109,988,000
115,033,000
114,639,000
132,136,000
265,454,000
171,914,000
166,464,000
200,128,000
247,512,000
355,402,000
386,123,000
313,608,000
340,639,000
444,720,000
504,100,000
412,798,000
533,301,000
645,601,000
0
590,219,000
0
0590,219,0000645,601,000533,301,000412,798,000504,100,000444,720,000340,639,000313,608,000386,123,000355,402,000247,512,000200,128,000166,464,000171,914,000265,454,000132,136,000114,639,000115,033,000109,988,000129,746,00096,786,000119,821,000150,766,000153,673,000193,751,000164,088,000147,944,000207,460,000195,762,000155,658,000116,002,000155,734,00053,396,00064,169,000163,362,000219,466,000220,002,000245,999,000220,007,000262,429,000194,396,000164,552,000178,358,00042,341,000-21,382,000-28,638,000-63,023,000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
-30,463,000
0
91,465,000
68,664,000
55,480,000
35,275,000
37,696,000
15,240,000
43,745,000
33,081,000
-18,479,000
-24,487,000
20,386,000
-19,115,000
-21,808,000
131,914,000
104,537,000
255,005,000
255,072,000
164,521,000
300,645,000
282,259,000
312,118,000
380,372,000
309,832,000
364,540,000
294,876,000
266,463,000
183,154,000
193,677,000
183,026,000
239,629,000
154,886,000
326,267,000
317,354,000
308,632,000
189,212,000
308,174,000
265,507,000
226,143,000
163,438,000
292,295,000
268,395,000
264,592,000
280,316,000
284,793,000
284,780,000
302,596,000
329,825,000
333,907,000
329,390,000
363,650,000
413,046,000
511,070,000
542,945,000
471,177,000
496,795,000
590,882,000
651,830,000
561,633,000
683,587,000
144,063,000
609,227,000
146,530,000
669,315,000
669,315,000146,530,000609,227,000144,063,000683,587,000561,633,000651,830,000590,882,000496,795,000471,177,000542,945,000511,070,000413,046,000363,650,000329,390,000333,907,000329,825,000302,596,000284,780,000284,793,000280,316,000264,592,000268,395,000292,295,000163,438,000226,143,000265,507,000308,174,000189,212,000308,632,000317,354,000326,267,000154,886,000239,629,000183,026,000193,677,000183,154,000266,463,000294,876,000364,540,000309,832,000380,372,000312,118,000282,259,000300,645,000164,521,000255,072,000255,005,000104,537,000131,914,000-21,808,000-19,115,00020,386,000-24,487,000-18,479,00033,081,00043,745,00015,240,00037,696,00035,275,00055,480,00068,664,00091,465,0000-30,463,00000



6.3. Balance Sheets

Currency in JPY. All numbers in thousands.




6.4. Cash Flows

Currency in JPY. All numbers in thousands.




6.5. Income Statements

Currency in JPY. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2025-03-31. Currency in JPY. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,912,323,000
Cost of Revenue-349,206,000
Gross Profit1,563,117,0001,563,117,000
 
Operating Income (+$)
Gross Profit1,563,117,000
Operating Expense-1,522,078,000
Operating Income41,039,00041,039,000
 
Operating Expense (+$)
Research Development327,651,000
Selling General Administrative843,032,000
Selling And Marketing Expenses-
Operating Expense1,522,078,0001,170,683,000
 
Net Interest Income (+$)
Interest Income7,874,000
Interest Expense-17,677,000
Other Finance Cost-0
Net Interest Income-9,803,000
 
Pretax Income (+$)
Operating Income41,039,000
Net Interest Income-9,803,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)31,237,00050,841,000
EBIT - interestExpense = 31,237,000
31,237,000
68,424,000
Interest Expense17,677,000
Earnings Before Interest and Taxes (EBIT)48,914,00048,914,000
Earnings Before Interest and Taxes (EBITDA)248,046,000
 
After tax Income (+$)
Income Before Tax31,237,000
Tax Provision--19,510,000
Net Income From Continuing Ops50,747,00050,747,000
Net Income50,747,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses1,871,284,000
Total Other Income/Expenses Net-9,802,0009,803,000
 

Technical Analysis of Astellas
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Astellas. The general trend of Astellas is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Astellas's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Astellas Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Astellas Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 11.87 < 11.88 < 12.13.

The bearish price targets are: 10.90 > 10.74 > 10.61.

Know someone who trades $ALPMY? Share this with them.πŸ‘‡

Astellas Pharma Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Astellas Pharma Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Astellas Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Astellas Pharma Inc. The current macd is 0.17086234.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Astellas price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Astellas. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Astellas price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Astellas Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartAstellas Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Astellas Pharma Inc. The current adx is 25.60.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Astellas shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Astellas Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Astellas Pharma Inc. The current sar is 11.01.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Astellas Pharma Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Astellas Pharma Inc. The current rsi is 60.40. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Astellas Pharma Inc Daily Relative Strength Index (RSI) ChartAstellas Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Astellas Pharma Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Astellas price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Astellas Pharma Inc Daily Stochastic Oscillator ChartAstellas Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Astellas Pharma Inc. The current cci is 54.41.

Astellas Pharma Inc Daily Commodity Channel Index (CCI) ChartAstellas Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Astellas Pharma Inc. The current cmo is 20.21.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Astellas Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartAstellas Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Astellas Pharma Inc. The current willr is -30.69306931.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Astellas is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Astellas Pharma Inc Daily Williams %R ChartAstellas Pharma Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Astellas Pharma Inc.

Astellas Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Astellas Pharma Inc. The current atr is 0.3443236.

Astellas Pharma Inc Daily Average True Range (ATR) ChartAstellas Pharma Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Astellas Pharma Inc. The current obv is 5,520,099.

Astellas Pharma Inc Daily On-Balance Volume (OBV) ChartAstellas Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Astellas Pharma Inc. The current mfi is 67.08.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Astellas Pharma Inc Daily Money Flow Index (MFI) ChartAstellas Pharma Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Astellas Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-30STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-09-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Astellas Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Astellas Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.404
Ma 20Greater thanMa 5011.312
Ma 50Greater thanMa 10010.775
Ma 100Greater thanMa 20010.207
OpenGreater thanClose11.640
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Astellas with someone you think should read this too:
  • Are you bullish or bearish on Astellas? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Astellas? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Astellas Pharma Inc

I send you an email if I find something interesting about Astellas Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Astellas Pharma Inc.

Receive notifications about Astellas Pharma Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.